Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, has reported earnings for the third quarter of 2023.
- The company reported a net loss of $227 million for the third quarter, compared to a profit of $141 million a year earlier
- On a per-share basis, it was a loss of $1.26 for the March quarter vs. earnings of $0.78 in the year-ago quarter
- The adjusted net loss was $0.09 per share, compared to net income of $1.04 per share in Q3 2022
- Third-quarter net revenue decreased 19% year-over-year to $1.04 billion
- Q3 adjusted EBITDA came in at $105 million, which is down 69% from the corresponding period of 2022
- For fiscal 2023, the management expects net revenue to be in the range of $4.225 billion to $4.325 billion
- The forecast for full-year adjusted net income is $169-210 million
Most Popular
Nike (NKE) looks set to beat hurdles and build a brighter future
Nike, Inc. (NYSE: NKE) has long been ruling the sportswear market but the company had its share of problems when headwinds like the pandemic and economic slowdown hit the business
Electronic Arts (EA): A few points to keep in mind if you have an eye on this gaming company
Shares of Electronic Arts Inc. (NASDAQ: EA) stayed green on Friday. The stock has dropped 7% over the past three months. The video game industry has been facing challenges as
Petros Pharma is focused on establishing mechanisms for Rx-to-OTC switch: CCO Fady Boctor
Petros Pharmaceuticals, Inc. (NASDAQ: PTPI) is a pharma company focused on identifying, developing, and commercializing therapeutics for men's health issues. It operates mainly through the business segments of Prescription Medications
